While our in vivo experiments with DBHB failed to increase the survival of B16F10 melanoma-bearing mice, it may be possible in the future to develop inhalation formulations to deliver DBHB directly to the lung (thus avoiding albumin binding) as we recently demonstrated for temozolomide [45,46]. The gene discussed is ALB; the disease is melanoma.